Aphria, an international producer and distributor of medicinal and recreational cannabis, completed the merger with Tilray, a pharmaceutical company that develops cannabis based medicines, drugs, drops, and oil products, in a $3.9bn deal. "Tilray is poised to strike and transform the industry with our highly scalable operational footprint, a curated portfolio of diverse medical and adult-use cannabis brands and products, a multi-continent distribution network, and a robust capital structure to fund our global expansion strategy and deliver sustained profitability and long-term value for our stakeholders," Irwin Simon, Aphria CEO. On April 15, 2021, Aphria's shareholders approved the proposed merger With Tilray.